Delcath Systems Grants Equity Award to Boost Talent and Oncology Innovations

Delcath Systems Enhances Workforce with New Equity Award Amid Innovative Oncology Solutions

Delcath Systems, Inc., an interventional oncology company that specializes in the treatment of liver cancers, has recently announced the granting of an equity award to a new employee who joined the company on November 4, 2024. This strategic move aligns with Delcath's commitment to attracting top talent in the field of oncology, particularly as it enhances its proprietary treatment solutions aimed at addressing challenging liver cancers. The equity award allows the purchase of 30,000 shares of the company's common stock under the terms of its 2023 Inducement Plan, with an exercise price set at $12.04, reflecting the stock's closing price on the grant date. This initiative not only incentivizes employee engagement but also aligns staff interests with the company’s growth objectives.

The vesting schedule for the stock options is structured to promote long-term employment, as one-third of the options will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal monthly installments over the following two years. Such a strategy underscores Delcath’s focus on fostering a stable and committed workforce, which is crucial for driving innovation in the competitive oncology market. The options are valid for ten years, compliant with Nasdaq Listing Rule 5635(c)(4), and reflect Delcath's goal of creating a robust organizational culture that prioritizes both employee commitment and company performance.

Delcath Systems continues to advance its proprietary treatment platforms, such as the HEPZATO KIT™ and CHEMOSAT® Hepatic Delivery System, designed for the localized delivery of high-dose chemotherapy to the liver. These innovative products aim to minimize systemic exposure, thereby reducing side effects related to chemotherapy. The HEPZATO KIT, approved by the FDA, utilizes the Hepatic Delivery System to isolate hepatic venous blood during treatment, significantly enhancing drug delivery to the targeted area while mitigating hepatotoxicity. This method is particularly beneficial for adult patients with metastatic uveal melanoma (mUM), addressing the critical need for effective therapies in cases of unresectable hepatic metastases.

In addition to enhancing its workforce, Delcath’s ongoing dedication to developing targeted treatment solutions positions the company as a leader in interventional oncology. By integrating advanced technologies with a skilled team, Delcath aims to achieve significant tumor response rates while prioritizing patient safety and improving overall treatment outcomes in liver cancer management. The recent equity grant is an important step in reinforcing the company’s strategic vision and commitment to innovation in oncology.